We performed a double-blind cross-over study with amantadine hydrochloride in 12 patients with Friedreich's disease and 2 with autosomal dominant cerebellar ataxia. Patients were randomly assigned to a placebo-amantadine or amantadine-placebo sequence. The interval between the treatments was two weeks. Patients were graded according to a functional ataxia scoring scale and videotaped in basal conditions and 90 min after a single oral dose of 100 mg amantadine or placebo. Three evaluators independently scored the videotapes. Statistical analysis showed no significant effect of amantadine in Friedreich's disease.
A double-blind cross-over trial of amantadine hydrochloride in Friedreich's ataxia / Filla, Alessandro; DE MICHELE, Giuseppe; Orefice, Giuseppe; F., Santorelli; L., Trombetta; S., Banfi; F., Squitieri; G., Napolitano; D., Puma; G., Campanella. - In: CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES. - ISSN 0317-1671. - ELETTRONICO. - 20:(1993), pp. 52-55.
A double-blind cross-over trial of amantadine hydrochloride in Friedreich's ataxia.
FILLA, ALESSANDRO;DE MICHELE, GIUSEPPE;OREFICE, GIUSEPPE;
1993
Abstract
We performed a double-blind cross-over study with amantadine hydrochloride in 12 patients with Friedreich's disease and 2 with autosomal dominant cerebellar ataxia. Patients were randomly assigned to a placebo-amantadine or amantadine-placebo sequence. The interval between the treatments was two weeks. Patients were graded according to a functional ataxia scoring scale and videotaped in basal conditions and 90 min after a single oral dose of 100 mg amantadine or placebo. Three evaluators independently scored the videotapes. Statistical analysis showed no significant effect of amantadine in Friedreich's disease.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
